Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

Health CarePharmaceuticals and Biotechnology
  • Price (CHF)53.20
  • Today's Change-0.50 / -0.93%
  • Shares traded4.76k
  • 1 Year change-35.59%
  • Beta1.3208
Data delayed at least 15 minutes, as of Aug 17 2022 16:31 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastroenterology and dermatology. It develops and manufactures products, which are distributed globally. The Company’s development pipeline is focused on Bowel Diseases, Colon Infections and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Its products include Lialda/Mezavant/Mesavancol and Uceri/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which develops for the treatment of travelers’ diarrhoea (TD), Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy; and Winlevi, which develops for the treatment of acne.

  • Revenue in CHF (TTM)75.84m
  • Net income in CHF34.24m
  • Incorporated--
  • Employees292.00
  • Location
    Cosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
  • Phone+353 18170370
  • Websitehttp://www.cosmopharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COPN:SWX since
Cassiopea SpAAnnounced04 Oct 202104 Oct 2021Announced-33.08%228.73m
Data delayed at least 15 minutes, as of Aug 17 2022 16:31 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Calliditas Therapeutics AB25.62m-53.42m583.79m71.00--6.63--23.02-11.38-11.385.4716.380.20771.0888.214,228,500.00-43.88-31.46-49.82-34.6817.60---211.31-288.515.36-88.310.1976--26,141.08---15.41--145.12--
Pharming Group N.V.189.96m19.57m621.29m321.0035.343.3616.653.310.02830.02830.28140.29720.50360.70755.76612,706.805.192.735.903.8789.8487.3610.304.394.53--0.4273---6.2762.49-57.62--66.17--
Pharmanutra SpA70.23m14.24m640.49m64.0045.3214.2543.449.191.521.527.514.841.110.81894.131,172,839.0022.6023.0629.7332.3397.0495.3920.2819.372.93--0.11350.8020.6615.75-2.1429.0318.07--
Surgical Science Sweden AB44.86m9.29m681.80m224.0058.852.0753.6615.562.542.5411.7372.320.19352.226.802,338,335.004.013.414.273.6769.0778.8020.7115.422.18--0.04320.00249.9847.90452.6692.434.25--
Ergomed PLC136.18m14.56m693.82m1.26k49.589.1035.005.230.25050.25052.341.361.20--5.0694,486.8512.784.2719.606.1340.7841.1810.693.85--53.750.03830.0037.2624.7630.90---2.38--
Puretech Health PLC16.33m-56.89m737.78m95.00--1.32--44.45-0.1734-0.17340.04961.690.018--6.07149,719.80-6.484.86-8.076.24-----360.65260.53----0.08180.0047.7631.45-1,111.83--9.02--
Zealand Pharma A/S33.74m-124.27m740.11m345.00--7.46--21.94-22.16-23.126.0216.420.12971.993.89731,901.40-47.76-31.81-57.58-37.0762.29---368.33-247.194.78--0.5268---17.194.85-20.24--53.47--
MorphoSys AG188.43m-822.30m760.43m648.00------3.93-24.93-24.935.71-0.8040.09552.221.79266,525.00-41.67-13.97-47.78-15.7378.40---436.39-89.382.91-4.031.09---45.1929.28-625.55--55.11--
Boiron SA439.65m27.58m804.93m2.77k28.901.5519.521.821.631.6325.9930.360.58641.504.89164,391.803.685.964.697.5071.9776.846.278.412.32--0.023246.86-11.37-5.828.95-18.15-10.06-9.90
BioGaia AB87.39m22.58m814.42m195.0037.905.3433.339.442.442.449.4317.300.4738----5,700,270.0012.2418.7013.3221.2773.0174.1825.8426.20--351.310.0075.305.097.999.204.2238.51-0.6484
Cosmo Pharmaceuticals NV75.84m34.24m891.20m292.0027.581.8418.9011.691.831.834.2227.390.11772.923.81261,524.705.32-2.095.51-2.1653.4359.6445.17-19.0510.81--0.268--6.77-0.7776374.292.30-14.33--
Eckert&Ziegler Strahlen und Mdzntchnk AG179.81m26.40m915.69m930.0035.054.9026.305.241.311.318.959.410.55612.435.25214,974.608.228.389.8210.1350.1847.8414.7912.772.39--0.117735.572.445.5262.2027.0840.1724.82
Fagron NV604.40m67.04m979.93m3.06k14.352.679.941.590.95080.95088.575.100.71363.5010.55204,438.407.957.309.939.9842.1844.0511.1410.411.2314.060.527812.973.216.352.35--7.01--
Nykode Therapeutics ASA32.45m-9.29m1.02bn128.00--5.79--31.94-0.3771-0.37711.166.280.1433--3.823,240,462.00-4.1025.30-4.5327.55-----28.6446.19----0.0357---84.20311.05-106.29--157.24--
Swedencare AB (publ)122.12m9.02m1.10bn513.00123.901.6541.169.050.61470.61479.6846.120.20732.308.514,751,254.001.534.781.605.0751.6757.827.3911.941.18-757.780.181232.49221.7770.4663.7641.06----
Valneva SE334.87m-69.31m1.15bn722.00--7.3856.383.44-0.7206-0.72063.421.380.5131.5813.82480,218.80-10.62-8.98-21.48-12.9246.0353.98-20.70-18.411.12-2.630.4377--215.5229.91-14.03--90.83--
Data as of Aug 17 2022. Currency figures normalised to Cosmo Pharmaceuticals NV's reporting currency: Swiss Franc CHF

Institutional shareholders

9.69%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 08 Mar 2022524.55k2.99%
The Vanguard Group, Inc.as of 05 Aug 2022263.03k1.50%
Baillie Gifford & Co.as of 30 Jun 2022237.07k1.35%
Norges Bank Investment Managementas of 31 Dec 2021163.76k0.93%
Credit Suisse Asset Management (Schweiz) AGas of 29 Jul 2022125.54k0.72%
BlackRock Fund Advisorsas of 03 Aug 2022114.12k0.65%
Sp-Fund Management Co. Ltd.as of 29 Jul 202293.60k0.53%
AMG Fondsverwaltung AGas of 30 Jun 202260.54k0.35%
Healthinvest Partners ABas of 30 Jun 202260.00k0.34%
Z�rcher Kantonalbank (Investment Management)as of 31 Dec 202057.54k0.33%
More ▼
Data from 31 Dec 2021 - 29 Jul 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.